EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - Biomira Inc. today announced that Robert Aubrey, Vice-President Marketing and Business Development, is to present at the Bio-Europe 2005 meeting being held in Dresden, Germany. Mr. Aubrey's partnering presentation is scheduled to be held on November 8, 2005 at 5:45 CET.
Mr. Aubrey's presentation will focus on in-licensing opportunities sought by Biomira as well as out-licensing opportunities:
- Liposomal Interleukin-2 (L-IL-2), available through Oncodigm BioPharma Inc., Biomira's spin-off company; - Biomira's synthetic adjuvants; and - Biomira's early stage licensing opportunity, BGLP40 Liposome Vaccine (L-BGLP40).
Mr. Aubrey will also highlight data announced last week on the Company's lead product candidate, BLP25 Liposome Vaccine (L-BLP25), a MUC1-based liposomal vaccine program in non-small cell lung cancer (NSCLC). Data from a phase 2b study show that patients with Stage IIIB locoregional NSCLC have a median survival of 30.6 months for the vaccine arm compared to 13.3 months for those not receiving the vaccine. The Company expects to initiate a phase 3 trial in 2006, in conjunction with its collaborator for L-BLP25, Merck KGaA of Darmstadt, Germany.
Biomira Inc.
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of the L-BLP25 phase 3 trial or the Company's ability to resolve vaccine manufacturing issues in a reasonable timeframe. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct or that the Company will have sufficient resources to fund clinical trials. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
BIOMIRA INC. 2011 - 94 St. Edmonton, AB, Canada T6N 1H1 Tel: (780) 450-3761 Fax: (780) 463-0871 http://www.biomira.com
Biomira Inc.CONTACT: Biomira Company: Media Relations, Bill Wickson, Manager, PublicRelations, (780) 490-2818; U.S. Media Contact: Jonathan Birt, FinancialDynamics, (212) 850-5634, jbirt@fd-us.com; Investor Relations, JaneTulloch, Director, Investor Relations, (780) 490-2812; U.S. InvestorContact: John Capodanno, Financial Dynamics, (212) 850-5705,jcapodanno@fd-us.com; To request a free copy of this organization's annualreport, please go to http://www.newswire.ca and click on Tools forInvestors.
